T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
EQT Corp
EQT
$33.8B
| $396M | 0.04% |
7,384,824
-4,471,925
| -38% | -$251M |
|
302
CBRE Group
CBRE
$42.7B
| $395M | 0.04% |
2,458,953
+64,509
| +3% | +$10.1M |
|
303
T. Rowe Price Value ETF
TVAL
$1.02B
| $393M | 0.04% |
11,160,913
+454,210
| +4% | +$15.7M |
|
304
GSK
GSK
$101B
| $387M | 0.04% |
7,894,729
-57,283
| -0.7% | -$2.67M |
|
305
OR Royalties Inc
OR
$6.31B
| $387M | 0.04% |
10,925,630
-27,858
| -0.3% | -$976K |
|
306
Comcast
CMCSA
$90.4B
| $384M | 0.04% |
12,861,233
-9,281,293
| -42% | -$265M |
|
307
Cardinal Health
CAH
$54.5B
| $384M | 0.04% |
1,866,287
-101,410
| -5% | -$19.1M |
|
308
Upwork
UPWK
$1.05B
| $381M | 0.04% |
19,231,377
+5,893,970
| +44% | +$108M |
|
309
Qiagen
QGEN
$8.88B
| $379M | 0.04% |
8,429,424
+906,589
| +12% | +$41.9M |
|
310
Hexcel
HXL
$7.74B
| $377M | 0.04% |
5,104,121
+790,320
| +18% | +$55.9M |
|
311
AT&T
T
$166B
| $376M | 0.04% |
15,156,229
-11,961,675
| -44% | -$303M |
|
312
Belden
BDC
$5.39B
| $376M | 0.04% |
3,225,244
+663,241
| +26% | +$77.4M |
|
|
BNY
313
Bank of New York Mellon
BNY
$111B
| $371M | 0.04% |
3,197,509
+68,799
| +2% | +$7.61M |
|
314
Bristol-Myers Squibb
BMY
$130B
| $371M | 0.04% |
6,879,475
-839,622
| -11% | -$40.4M |
|
315
Pinduoduo
PDD
$127B
| $370M | 0.04% |
3,262,954
-2,107,418
| -39% | -$262M |
|
316
PPG Industries
PPG
$25.5B
| $366M | 0.04% |
3,568,691
-123,102
| -3% | -$12.4M |
|
317
Viper Energy
VNOM
$15.2B
| $364M | 0.04% |
9,412,009
-1,385,499
| -13% | -$52.5M |
|
318
Automatic Data Processing
ADP
$107B
| $362M | 0.04% |
1,407,711
-47,550
| -3% | -$12.7M |
|
319
Corebridge Financial
CRBG
$15.1B
| $362M | 0.04% |
11,993,696
-26,213,171
| -69% | -$806M |
|
320
State Street
STT
$52.2B
| $356M | 0.04% |
2,760,886
-258,225
| -9% | -$30.9M |
|
321
Vistra
VST
$49.2B
| $355M | 0.04% |
2,197,728
-154,825
| -7% | -$28.2M |
|
322
RPM International
RPM
$14.7B
| $346M | 0.04% |
3,327,217
+161,561
| +5% | +$17.5M |
|
323
Amgen
AMGN
$225B
| $342M | 0.04% |
1,043,757
-11,823
| -1% | -$3.75M |
|
|
SNDK
324
Sandisk
SNDK
$196B
| $341M | 0.04% |
1,437,171
-1,870,903
| -57% | -$375M |
|
325
Kenvue
KVUE
$36.5B
| $341M | 0.04% |
19,751,964
-95,331,101
| -83% | -$1.56B |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.